Last reviewed · How we verify
Ethamolin (ETHANOLAMINE OLEATE)
Ethamolin, marketed by Qol Medcl, is an ethanolamine oleate formulation used for preventing rebleeding in esophageal varices, positioned in a niche but critical therapeutic area. Its key strength lies in its mechanism of action, which disrupts cell membranes to reduce inflammation and relieve pain, offering a unique approach compared to other same-class competitors. The primary risk is the upcoming patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | ETHANOLAMINE OLEATE |
|---|---|
| Sponsor | Qol Medcl |
| Drug class | ethanolamine oleate |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1988 |
Approved indications
- Prevention of rebleeding in esophageal varices
Common side effects
- pleural effusion/infiltration
- esophageal ulcer
- pyrexia
- retrosternal pain
- esophageal stricture
- pneumonia
Key clinical trials
- Effectiveness of Diode Laser and Sclerotherapy in Treatment of Oral Pyogenic Granuloma (NA)
- Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection (PHASE3)
- Scleroligation for Eradication of Gastroesophageal Varices. (PHASE3)
- Treatment Schistosomal Portal Hypertension: Efficacy of Endoscopy or Surgery (NA)
- Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies (PHASE1,PHASE2)
- Injection Snoreplasty: Comparison Between Ethanol and Ethanolamine Oleate (NA)
- A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ethamolin CI brief — competitive landscape report
- Ethamolin updates RSS · CI watch RSS
- Qol Medcl portfolio CI